Plain-English translation of NCT05025813 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether an immune-boosting medication called , given before surgery, can help shrink advanced cutaneous squamous cell carcinoma (a type of skin cancer) on the head and neck. The hope is that by giving this treatment first, doctors can then perform less extensive surgery and avoid or reduce radiation therapy. The trial will provide important information about how well the medication works and help identify which patients benefit most.
Advanced skin cancers in the head and neck area normally require major surgery and radiation that can cause significant side effects and disfigurement. This trial aims to see whether this medication can shrink tumors beforehand, allowing doctors to perform gentler surgery and spare more patients from radiation therapy.
You likely qualify if…
You likely don't qualify if…
You would receive four doses of the immune therapy medication by IV infusion over about 9 weeks. After that, imaging scans would check if the tumor has shrunk. Depending on the results, you may then have surgery (with or without radiation afterward) and continue with additional doses of the medication over several months. Throughout the trial, you'll have regular visits for blood tests, scans, and check-ups to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Australia